Corona Remedies Ltd
Corona Remedies Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #67 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
CORONA Remedies aims for 15% compound annual growth rate (CAGR) in revenue over the next 3 to 4 years. CORONA Remedies targets a 15% CAGR revenue growth over the next 3 to 4 years.
From Corona Remedies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CORONA Remedies aims for 15% compound annual growth rate (CAGR) in revenue over the next 3 to 4 years.
- The target for profit after tax (PAT) or earnings per share (EPS) growth is around 20% year-on-year for the next 3 to 4 years.
- Revenue growth is generally steady with minor seasonal variations; Q3 sees slightly less growth due to festive season.
- The company plans to expand its sales force by 5-7% annually, supporting growth and new therapy launches.
2 more points from Corona Remedies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Corona Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- CORONA Remedies is investing in a new hormonal manufacturing plant in Ahmedabad, which has received the state Schedule M license and is expected to commence commercial production by Q2-end or early Q3 of FY '27.
- The company aims to obtain WHO and EU GMP certifications for this plant by the end of FY '27 to ramp up its international hormonal products business.
- There is a significant solar power investment: an existing 1.3 MW solar plant at Bhayla and a planned 4.25 MW solar park covering 11.9 acres, aimed at reducing electricity costs and supporting ESG initiatives.
2 more points from Corona Remedies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Corona Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Corona Remedies Ltd said on order book & pipeline — free account, 30 seconds.
Corona Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹353 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Corona Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Corona Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Corona Remedies Ltd Q3 FY26 results?
CORONA Remedies aims for 15% compound annual growth rate (CAGR) in revenue over the next 3 to 4 years. CORONA Remedies targets a 15% CAGR revenue growth over the next 3 to 4 years.
What is Corona Remedies Ltd share price analysis?
Corona Remedies Ltd currently shows a neutral. The stock trades at a P/E of 60.6 with a market cap of ₹12,823 Cr. Investors should review the full earnings analysis for detailed insights.
Is Corona Remedies Ltd planning capital expenditure?
CORONA Remedies is investing in a new hormonal manufacturing plant in Ahmedabad, which has received the state Schedule M license and is expected to commence commercial production by Q2-end or early Q3 of FY '27.
Keep Corona Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.